A dark blue background with various hexagonal shapes and lines clustered on the left side, representing rad to rad learning, gradually fading into open space on the right.

Rad to Rad Learning: Olecranon Bursitis

The Radiology Partners (RP) MSK National Subspecialty Division (NSD) presents our newest Rad to Rad Learning case.

Peer Learning Opportunity

Is this soft tissue swelling?

Septic bursitis is less common but often requires immediate medical attention.

Lateral view of an elbow joint from a Rad to Rad Learning X-ray and CT scan.

1/3 of all olecranon bursitis cases are septic.

Magnetic resonance imaging (MRI) scan showing an area of signal intensity in the soft tissues for Rad to Rad Learning.

Practical Insights

- Sequalae of untreated septic bursitis, if untreated, can lead to pyomyositis, septic arthritis, or osteomyelitis.
- Include in differential for soft tissue swelling over olecranon.
- Inflammatory conditions associated with olecranon bursitis (CPPD, gout, RA).
- Trauma (prone to injury with superficial location).

Takeaway: One of the few MSK soft tissue diagnoses identified by x-ray.

Shared to improve patient safety and healthcare delivery in the provision of radiology services. The circumstances and facts are changed, altered, or deidentified to preserve confidentiality. Privileges have not been waived.The MSK Radiology National Subspecialty Division (NSD) is part of RP’s Clinical Value Team, which works to elevate patient care and enhance value through innovation, collaboration and education. To advance this goal, our radiologists and advanced practice providers are committed to sharing peer learning as valuable reminders and insights about what we encounter in our day-to-day practice. Check back here and on X, LinkedIn and Instagram to see these common cases and our findings.

Visit the Clinical Resources page for more cases and to see what we’ve developed to enhance best practice recommendations, elevate image quality and patient care and update current standards throughout RP’s network of practices, all to deliver excellent radiology services to patients, referring clinicians and client partners.

Radiology Partners, through RP Clinical Services and its managed practices, together with Mosaic Clinical Technologies, Inc., its technology and AI division, is the leading provider of technology-enabled radiology services in the U.S., serving more than 3,400 hospitals and other healthcare facilities with high-quality radiology, technology and artificial intelligence solutions. As a physician-led and physician-owned practice, our mission is to transform radiology by innovating across clinical value, technology, and service, while elevating the role of radiology and radiologists in healthcare. For the latest news from RP, follow us on X, LinkedIn, Instagram, YouTube and the blog.

Rad to Rad Learning: Non-Mass Lesions on US

The Radiology Partners (RP) Breast Imaging National Subspecialty Division (NSD) presents our newest Rad to Rad Learning case.

Peer Learning Opportunity

These are images of a patient with heterogeneously dense breasts who was recommended for a supplemental screening breast US.

Comparison of current and prior-year screening mammograms used for Rad to Rad learning.

The patient was found to have a new “non-mass” lesion in the right 2:00 axis which was recommended for biopsy. It was DCIS, stage 0 breast cancer. It appeared as a serpiginous, hypoechoic structure.

Medical imaging featuring Rad to Rad Learning, showing three ultrasound scans of breast tissue with a corresponding mammogram on the right.

Practical Insights

- New terminology added to 2025 BI-RADS.
- Can be identified as distinctly different from normal tissue, seen in 3 dimensions but lacks the discrete margination of a mass and cannot be assigned a specific shape.
- Often subtle and may be detected only because the background tissue is disrupted. If it is a new or isolated finding, it may be considered suspicious.

Takeaway: New ultrasound descriptor that could correlate with benign and malignant findings.

Shared to improve patient safety and healthcare delivery in the provision of radiology services. The circumstances and facts are changed, altered, or deidentified to preserve confidentiality. Privileges have not been waived.The Breast Imaging National Subspecialty Division (NSD) is part of RP’s Clinical Value Team, which works to elevate patient care and enhance value through innovation, collaboration and education. To advance this goal, our radiologists and advanced practice providers are committed to sharing peer learning as valuable reminders and insights about what we encounter in our day-to-day practice. Check back here and on X, LinkedIn and Instagram to see these common cases and our findings.

Rad to Rad Learning: Imaging Technique Matters

The Radiology Partners (RP) Breast Imaging National Subspecialty Division (NSD) presents our newest Rad to Rad Learning case.

Peer Learning Opportunity

Something is missing from this right CC view.

In the original scan, the image was exaggerated laterally, which resulted in excluded medial tissue.

A mammogram image showing the soft tissue structure of a breast for Rad to Rad Learning.

A second scan was performed with proper technique, and a mass that was previously out of frame became visible.

Side-by-side mammogram images for Rad to Rad learning, with a purple arrow in the right image pointing to a spot in the lower breast tissue.

Practical Insights

- Do not accept suboptimal patient positioning.
- For CC, the posterior nipple line should bisect the breast into equal halves, with only fat or muscle in the retroglandular space.
- For MLO, the pectoralis muscle should extend to the posterior nipple line with a convex anterior margin of the pectoralis muscle. The inframammary fold should be open.

Takeaway: You can’t find cancers you can’t see.

Shared to improve patient safety and healthcare delivery in the provision of radiology services. The circumstances and facts are changed, altered, or deidentified to preserve confidentiality. Privileges have not been waived.The Breast Imaging National Subspecialty Division (NSD) is part of RP’s Clinical Value Team, which works to elevate patient care and enhance value through innovation, collaboration and education. To advance this goal, our radiologists and advanced practice providers are committed to sharing peer learning as valuable reminders and insights about what we encounter in our day-to-day practice. Check back here and on X, LinkedIn and Instagram to see these common cases and our findings.

Blue background with a dark, geometric pattern of interlocking hexagons and connecting dots representing mammography and AI.

Washington Recognizes AI as Medical Technology. Reimbursement Must Follow.

Every year, millions of women undergo mammograms to screen for breast cancer. What many don’t realize is that the same image may also reveal their risk for another, often silent threat: cardiovascular disease, the leading cause of death among women in the United States.

Thanks to advances in artificial intelligence (AI), clinicians can now use routine mammograms to identify breast arterial calcifications (BAC), a marker associated with heart disease and stroke. These insights require no additional appointments, imaging tests, or radiation exposure. They simply use the information already available.

This is exactly the kind of common-sense innovation our healthcare system needs to embrace. Unfortunately, payment policies have not kept pace.

One example is Radiology Partners’ Mammo Enhance Heart™ program, which uses an FDA-cleared AI tool to identify BAC during routine mammograms. Research shows that women with BAC are approximately 51 percent more likely to develop heart disease or stroke. By identifying at-risk women earlier, AI can help connect patients with appropriate follow-up care before serious symptoms emerge.

The program effectively creates a two-for-one screening opportunity. Importantly, specialists remain at the center of the process. Radiologists review and confirm the AI’s findings and share results with patients and their referring providers. This is what responsible AI adoption looks like – technology augmenting clinical expertise rather than replacing it.

Yet many women cannot access these healthcare innovations because our payment system was not designed to support them. Current reimbursement models pay for isolated clinical services but not for the infrastructure needed to connect them, such as the implementation of safe, responsible AI, which includes validation, clinician training, workflow integration and ongoing monitoring.

In fact, the Centers for Medicare & Medicaid Services (CMS) recently acknowledged the growing importance of AI by recognizing certain AI-enabled software as a medical technology worthy of reimbursement consideration. While an important first step, the mere recognition of AI as a clinical technology is not the same as creating a sustainable pathway for its adoption.

Washington has recognized AI as a medical technology. It now needs to pay for the infrastructure that allows patients to benefit from it.

Without support for these foundational capabilities, many hospitals and health systems simply cannot afford to adopt proven AI tools, limiting patient access and slowing innovation.

Policymakers should modernize reimbursement to support the infrastructure that enables responsible AI adoption. A payment model that helps health systems build these capabilities would allow more women to benefit from clinically validated technologies while ensuring appropriate oversight and accountability.

The promise of AI in women’s health is no longer theoretical. It is already helping clinicians identify risk earlier and giving women information that could save their lives. A mammogram that can help detect both breast cancer and heart disease is a powerful reminder of what’s possible when smart innovation meets existing clinical care.

Dr. Arthy Saravanan is the Associate Chief Medical Officer for Recruiting at Radiology Partners. Justine Jamero, MHA, co-leads health policy and advocacy at Radiology Partners.

 Radiology Partners, Inc., through RP Clinical Services and its managed practices, together with Mosaic Clinical Technologies, Inc., its technology and AI division, is the leading provider of technology-enabled radiology services in the U.S., serving more than 3,400 hospitals and other healthcare facilities with high-quality radiology, technology and artificial intelligence solutions. As a physician-led and physician-owned practice, our mission is to transform radiology by innovating across clinical value, technology, and service, while elevating the role of radiology and radiologists in healthcare. For the latest news from RP, follow along on our blog and on X, LinkedIn, Instagram and YouTube. Interested in learning about career opportunities? Visit our careers page.   

Rad to Rad Learning: Masses Obscured by Implants

The Radiology Partners (RP) Breast Imaging National Subspecialty Division (NSD) presents our newest Rad to Rad Learning case.

Peer Learning Opportunity

How much time do you spend looking at implant-included views?

Proper technique is important for implant-included views. While they can be more difficult, they can also provide more information.

Four mammogram images showing left breast views with and without the breast implant displaced, provided for Rad to Rad Learning.

W/L adjustment on the implant-included L CC view shows an irregular mass seen through the radiolucent saline implant. 2) US of mass. 3) MR of mass.

Practical Insights

- Implants obscure breast tissue.
- Standard implant imaging includes both implant-included and implant displaced (Eklund) views.
- Implant displaced (ID) views exclude posterior tissues.
- Saline implants are radiolucent.

Takeaway: Implant views are critical!

Shared to improve patient safety and healthcare delivery in the provision of radiology services. The circumstances and facts are changed, altered, or deidentified to preserve confidentiality. Privileges have not been waived.The Breast Imaging National Subspecialty Division (NSD) is part of RP’s Clinical Value Team, which works to elevate patient care and enhance value through innovation, collaboration and education. To advance this goal, our radiologists and advanced practice providers are committed to sharing peer learning as valuable reminders and insights about what we encounter in our day-to-day practice. Check back here and on X, LinkedIn and Instagram to see these common cases and our findings.

Gradient blue background with repeated, thin-outlined rp letters—subtly referencing Radiology Partners—arranged diagonally in the lower right corner, fading as they move upward and left.

Radiology Partners Announces Expiration of and Results of Consent Solicitation for its Second Lien Senior Secured PIK Notes due 2030

NASHVILLE, Tenn., October 12, 2026 – Radiology Partners, Inc., a Delaware corporation (the “Company”), today announced the expiration and results of its previously announced solicitation of consents (“Consents” and such solicitation the “Consent Solicitation”) from the noteholders (each, a “Noteholder”) of the Company’s Second Lien Senior Secured PIK Notes due 2030 (the “Notes”) to adopt certain proposed amendments (the “Proposed Amendments”) to the indenture governing the Notes (the “Indenture”) to facilitate the consummation of the previously announced acquisition of Everlight Radiology Holdings Pty Ltd (the “Everlight Acquisition”). The Consent Solicitation was made pursuant to the terms of and subject to the conditions set forth in the consent solicitation statement, dated October 5, 2026 (the “Consent Solicitation Statement”).

The Consent Solicitation expired at 5:00 P.M., New York City time, on October 9, 2026 (the “Expiration Time”). As of the Expiration Time, the Consents from Noteholders representing 99.21% of the aggregate principal of Notes outstanding have been validly delivered (and not validly revoked), which exceeds the requisite consents required pursuant to the terms of the Indenture for the Proposed Amendments to be approved and binding on all of the Noteholders and any subsequent Noteholder (the “Requisite Consents”).

As a result, each Noteholder that validly delivered (and did not validly revoke) a Consent prior to the Expiration Time and whose Consent the Company accepted (each such Noteholder, a “Consenting Holder” and the Notes held by such Consenting Holders and validly submitted for consents in the Consent Solicitation (and not validly revoked), collectively, the “Consenting Notes”) are eligible to receive consideration equal to a pro rata portion of 2.0% of the aggregate principal amount of outstanding Notes as of the date of the Consent Solicitation Statement (the “Consent Fee”). The payment of the Consent Fee remains conditioned upon satisfaction or waiver (as applicable) of certain conditions set out in the Consent Solicitation Statement, including the consummation of the Everlight Acquisition. The Consent Fee is expected to be paid in cash only to Consenting Holders substantially concurrently with the consummation of the Everlight Acquisition. No Consent Fee shall be paid if the Everlight Acquisition does not occur. The Company is required to commence an offer to purchase only Consenting Notes for cash (the “Future Tender Offer”) within ten (10) business days following the closing date of the Everlight Acquisition, in an aggregate amount equal to 8% of the aggregate principal amount of Notes outstanding (subject to the Additional Repurchase Amount (as defined in the Consent Solicitation Statement)), at a price of 100% of the aggregate principal amount of such Notes, plus accrued and unpaid interest, as further described in the Consent Solicitation Statement and to be set forth in the offer to purchase related to the Future Tender Offer.

Global Bondholder Services Corporation served as tabulation agent (the “Tabulation Agent”) for Consents with respect to the Consent Solicitation and as information agent (the “Information Agent”) with respect to the Consent Solicitation Statement. Barclays Capital Inc. acted as solicitation agent with respect to the Consent Solicitation (the “Solicitation Agent”). Wilmington Trust, National Association, as Trustee and Notes Collateral Agent, is not involved in the Consent Solicitation and has no responsibility relating to such Consent Solicitation. The contact information for the Tabulation Agent, the Information Agent and the Solicitation Agent is set forth below.

About Radiology Partners

Radiology Partners, Inc., through RP Clinical Services and its managed practices, together with Mosaic Clinical Technologies, Inc., its technology and AI division, is the leading provider of technology-enabled radiology services in the U.S., serving more than 3,400 hospitals and other healthcare facilities with high-quality radiology, technology and artificial intelligence solutions. As a physician-led and physician-owned practice, our mission is to transform radiology by innovating across clinical value, technology, and service, while elevating the role of radiology and radiologists in healthcare.

No Offer or Solicitation

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Consent Solicitation, or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this communication is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration requirements.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made herein may be deemed “forward-looking statements” within the meaning of federal securities laws, including any statements regarding the payment of the Consent Fee, the Future Tender Offer and the consummation of the Everlight Acquisition. Any statements that are not statements of historical fact should be considered forward-looking statements. In many cases, forward-looking statements can generally be identified by the use of forward-looking terminology such as “may,” “plan,” “predict,” “expect,” “estimate,” “intend,” “would,” “will,” “could,” “should,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar expressions. All forward-looking statements speak only as of the date of this press release. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements are reasonable, such plans, intentions or expectations may not be achieved. The Company cautions Noteholders that any forward-looking statements are subject to risks and uncertainties, including risks in connection with the timing of the consummation of the Everlight Acquisition, our ability to satisfy closing conditions for the Everlight Acquisition and anticipated benefits flowing from the Everlight Acquisition, any of which may cause actual results and future trends to differ materially from those projected, stated or implied by the forward-looking statements. In addition, the Company encourages Noteholders to read the risks and uncertainties under the heading “Risk Factors” in the Company’s annual report and the heading “Certain Risk Factors Relating to the Consent Solicitation” in the Consent Solicitation Statement. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Questions regarding the Consent Solicitation Statement and the Indenture may be directed to the Information Agent at the address below:

Global Bondholder Services Corporation
65 Broadway, Suite 404
New York, New York 10006
Banks and Brokers Call Collect: (212) 430-3774
All Others Call Toll-Free: (855) 654-2015
Email: contact@gbsc-usa.com with reference to “Radiology Partners” in the subject line

Questions concerning the terms of the Consent Solicitation may also be directed to the Solicitation Agent:

Barclays Capital Inc.
745 Seventh Avenue, 5th Floor
New York, NY 10019
Collect: (212) 528-7581
Email: us.lm@barclays.com
Attention: Liability Management Group

Rad to Rad Learning: Missed Breast Cancer on Chest CT

The Radiology Partners (RP) Breast Imaging National Subspecialty Division (NSD) presents our newest Rad to Rad Learning case.

Peer Learning Opportunity

A 70 y/o female presented to the ER with palpitations and received a chest CT. She was ultimately diagnosed with atrial fibrillation. What did the radiologist miss?

In this case, the radiologist missed an invasive mammary carcinoma! Incidental breast cancers on chest CTs are missed 64% of the time.

Axial CT scan slice of the human chest, used for Rad to Rad Learning, showing the heart and major blood vessels.

Remember to review breast tissue in your search pattern.

Medical imaging panels for Rad to Rad Learning showing a CT scan with an arrow pointing to a breast mass, a mammogram with a focal density, and an ultrasound image labeled Left breast 12 oclock 4 cmfn anti-radial.

Practical Insights

- During a Chest CT the primary focus is on evaluating other anatomy, and breast tissue is easy to overlook.
- Not all eligible women undergo mammographic screening, and incidental findings on unrelated chest CTs are the only way their cancer is found.
- Remember to review breast tissue in FOV.
- Early detection saves lives.

Takeaway: Chest CTs include breasts!

Shared to improve patient safety and healthcare delivery in the provision of radiology services. The circumstances and facts are changed, altered, or deidentified to preserve confidentiality. Privileges have not been waived.The Breast Imaging National Subspecialty Division (NSD) is part of RP’s Clinical Value Team, which works to elevate patient care and enhance value through innovation, collaboration and education. To advance this goal, our radiologists and advanced practice providers are committed to sharing peer learning as valuable reminders and insights about what we encounter in our day-to-day practice. Check back here and on X, LinkedIn and Instagram to see these common cases and our findings.

Radiology Partners Announces Commencement of Consent Solicitation for its Second Lien Senior Secured PIK Notes due 2030

NASHVILLE, Tenn., October 5, 2026 – Radiology Partners, Inc., a Delaware corporation (the “Company”), today announced that it has commenced a solicitation of consents (“Consents” and such solicitation the “Consent Solicitation”) from the noteholders (each, a “Noteholder”) of the Company’s Second Lien Senior Secured PIK Notes due 2030 (the “Notes”) to adopt certain proposed amendments (the “Proposed Amendments”) to the indenture governing the Notes (the “Indenture”) to facilitate the consummation of the previously announced acquisition of Everlight Radiology Holdings Pty Ltd (the “Everlight Acquisition”).

The Consent Solicitation will expire at 5:00 P.M., New York City time, on October 9, 2026 or such later time and date to which such Consent Solicitation may be extended or earlier terminated (such time and date, the “Expiration Time”). Noteholders must deliver, and not revoke, valid Consents prior to the Expiration Time to be eligible to receive the Consent Fee (as defined below). Consents may be revoked at any time prior to the “Consent Date” which is the earlier of (a) the Effective Date (as defined in the Consent Solicitation Statement) for the Consent Solicitation and (b) 5:00 P.M., New York City time, on October 9, 2026 or such later time and date to which such date may be extended. The Consent Solicitation is subject to the satisfaction or waiver (as applicable) of certain conditions set forth in the consent solicitation statement, dated October 5, 2026 (the “Consent Solicitation Statement”).

The Consents of the Noteholders of at least a majority in aggregate principal amount of all the outstanding Notes are required pursuant to the terms of the Indenture for the Proposed Amendments to be approved and binding on all of the Noteholders and any subsequent Noteholder (the “Requisite Consents”). As of the date hereof, Noteholders holding approximately 60% of the aggregate principal amount of the outstanding Notes, which would exceed the Requisite Consents, have entered into a support agreement with the Company (the “Support Agreement”) pursuant to which they have committed to participate in the Consent Solicitation and provide their Consent to the Proposed Amendments prior to the Expiration Time. Therefore, the Company expects to receive the necessary Consents to adopt the Proposed Amendments prior to the Expiration Time.

Consents may be delivered in minimum denominations of $1.00 and integral multiples of $1.00 in excess thereof. The Company is offering each Noteholder that validly grants (and does not validly revoke) a Consent prior to the Expiration Time and whose Consent the Company accepts (each such Noteholder, a “Consenting Holder” and the Notes held by such Consenting Holders and validly submitted for consents in this Consent Solicitation (and not validly revoked), collectively, the “Consenting Notes”) consideration equal to a pro rata portion of 2.0% of the aggregate principal amount of outstanding Notes as of the date of the Consent Solicitation Statement (the “Consent Fee”). The payment of the Consent Fee is conditioned upon satisfaction or waiver (as applicable) of certain conditions set out in the Consent Solicitation Statement, including obtaining the Requisite Consents and the consummation of the Everlight Acquisition. The Consent Fee is expected to be paid in cash only to Consenting Holders in this Consent Solicitation substantially concurrently with the consummation of the Everlight Acquisition. No Consent Fee shall be paid if the Everlight Acquisition does not occur.

Pursuant to the Support Agreement, the Company is also required to commence an offer to purchase only Consenting Notes for cash (the “Future Tender Offer”) within ten (10) business days following the closing date of the Everlight Acquisition, in an aggregate amount equal to 8% of the aggregate principal amount of Notes outstanding (subject to the Additional Repurchase Amount (as defined in the Consent Solicitation Statement) as of (i) the early expiration time of the Future Tender Offer or (ii) to the extent no early expiration time exists, the expiration time of the Future Tender Offer (any of (i) or (ii), as the case may be, the “Future Tender Offer Expiration Time”) (which shall include any increase in principal amount resulting from any PIK Payment (as defined in the Indenture) made on or prior to the Future Tender Offer Expiration Time) (the “Repurchase Amount”) at a price of 100% of the aggregate principal amount of such Notes, plus accrued and unpaid interest, in each case, to be set forth in the offer to purchase related to this tender offer. The Repurchase Amount is subject to automatic increase by the Additional Repurchase Amount for each thirty (30)-day period following the closing date of the Everlight Acquisition during which the Future Tender Offer is not completed, as further described in the Consent Solicitation Statement.

The Consent Solicitation is being made to all holders of Notes held through The Depository Trust Company (“DTC”) by participants in DTC (“DTC Participants”). A beneficial owner of an interest in a Note (“Beneficial Owner”) held through a DTC Participant must properly instruct such DTC Participant to cause a Consent to be given by such DTC Participant with respect to such Note. Consents must be electronically delivered in accordance with DTC’s Automated Tender Offer Program procedures. Beneficial Owners whose Notes are held through a broker, dealer, commercial bank, trust company or other nominee should note that their nominee may establish a deadline earlier than the Consent Date by which instructions must be received by them in relation to the Consent Solicitation and, accordingly, Beneficial Owners are urged to contact their nominees as soon as possible to learn of any deadlines established by their nominees in relation to the Consent Solicitation.

The Company expressly reserves the right, at any time prior to the Effective Date, to amend any of the terms of the Consent Solicitation in any manner it deems necessary or advisable in its sole discretion, in accordance with applicable law and its contractual obligations. The Consent Solicitation may be terminated at any time prior to, or after, the Expiration Time and prior to the Effective Date, in the Company’s sole discretion, whether or not the Requisite Consents have been received.

The Company has appointed Global Bondholder Services Corporation as tabulation agent (the “Tabulation Agent”) for Consents with respect to the Consent Solicitation and as information agent (the “Information Agent”) with respect to the Consent Solicitation Statement. The Company has appointed Barclays Capital Inc. as solicitation agent with respect to the Consent Solicitation (the “Solicitation Agent”). Wilmington Trust, National Association, as Trustee and Notes Collateral Agent, is not involved in the Consent Solicitation and has no responsibility relating to such Consent Solicitation. The contact information for the Tabulation Agent, the Information Agent and the Solicitation Agent is set forth below.

Noteholders are urged to carefully read the entire Consent Solicitation Statement, including the information presented under “Certain Risk Factors Relating to the Consent Solicitation” and “Statement Regarding Forward-Looking Statements” before making any decision with respect to the Consent Solicitation. None of the Company, the Solicitation Agent, the Trustee, the Notes Collateral Agent, the Information Agent or the Tabulation Agent makes any recommendation as to whether or not Noteholders should deliver Consents in response to the Consent Solicitation. Each Noteholder must make its own decision as to whether or not to deliver a Consent.

About Radiology Partners

Radiology Partners, Inc., through RP Clinical Services and its managed practices, together with Mosaic Clinical Technologies, Inc., its technology and AI division, is the leading provider of technology-enabled radiology services in the U.S., serving more than 3,400 hospitals and other healthcare facilities with high-quality radiology, technology and artificial intelligence solutions. As a physician-led and physician-owned practice, our mission is to transform radiology by innovating across clinical value, technology, and service, while elevating the role of radiology and radiologists in healthcare.

No Offer or Solicitation

Cautionary Note Regarding Forward-Looking Statements

Certain statements made herein may be deemed “forward-looking statements” within the meaning of federal securities laws, including any statements regarding the consummation of the Consent Solicitation. Any statements that are not statements of historical fact should be considered forward-looking statements. In many cases, forward-looking statements can generally be identified by the use of forward-looking terminology such as “may,” “plan,” “predict,” “expect,” “estimate,” “intend,” “would,” “will,” “could,” “should,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar expressions. All forward-looking statements speak only as of the date of this press release. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements are reasonable, such plans, intentions or expectations may not be achieved. The Company cautions Noteholders that any forward-looking statements are subject to risks and uncertainties, including risks in connection with the timing of the consummation of the Everlight Acquisition, our ability to satisfy closing conditions for the Everlight Acquisition and anticipated benefits flowing from the Everlight Acquisition, any of which may cause actual results and future trends to differ materially from those projected, stated or implied by the forward-looking statements. In addition, the Company encourages Noteholders to read the risks and uncertainties under the heading “Risk Factors” in the Company’s annual report and the heading “Certain Risk Factors Relating to the Consent Solicitation” in the Consent Solicitation Statement. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Questions and requests for assistance or additional copies of the Consent Solicitation Statement and the Indenture may be directed to the Information Agent at the address below. Noteholders should retain their Notes and not deliver any such Notes to the Tabulation Agent or the Information Agent. Duly executed Consents should be delivered through DTC, as described in the Consent Solicitation Statement:

Global Bondholder Services Corporation

65 Broadway, Suite 404

New York, New York 10006

Banks and Brokers Call Collect: (212) 430-3774

All Others Call Toll-Free: (855) 654-2015

Email: contact@gbsc-usa.com with reference to “Radiology Partners” in the subject line

A Noteholder may also contact such Noteholder’s broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Consent Solicitation.

Questions concerning the terms of this Consent Solicitation should be directed to the Solicitation Agent:

Barclays Capital Inc.

745 Seventh Avenue, 5th Floor

New York, NY 10019

Collect: (212) 528-7581

Email: us.lm@barclays.com

Attention: Liability Management Group

Singleton Associates and Blue Cross and Blue Shield of Texas Sign Long-Term Agreement to Protect In-Network Access to Radiology Care in Texas

(Nashville, TN) DATE, 2026 – Singleton Associates, P.A. (Singleton Associates), a Radiology Partners-affiliated practice, and Blue Cross and Blue Shield of Texas (BCBSTX) have reached a new multi-year agreement, effective November 1, 2026.

This long-term agreement represents a significant achievement for patients, providers, and healthcare organizations across Texas, reflecting both organizations’ commitment to network stability, continuity of care and uninterrupted access to high-quality, in-network diagnostic and interventional radiology care.

Together, Singleton Associates and BCBSTX coordinated closely to reach an agreement, recognizing that fair, sustainable reimbursement and strong network relationships are in the best interests of patients, providers, health plans and the healthcare system as a whole.

“We commend BCBSTX for recognizing the realities of the severe, nationwide radiologist shortage and the importance of partnering to ensure sustainable rates and access to critical emerging technologies to preserve access, reduce total system cost and enhance detection of life-threatening disease,” said Dr. Byron Christie from Singleton Associates. “We are pleased to continue our partnership with BCBSTX and believe this agreement demonstrates what is possible when health plans and providers work together to solve complex healthcare challenges.”

Singleton Associates provides a broad range of hospital-based and outpatient imaging services across Texas, including 24/7 emergency radiology coverage and highly specialized diagnostic and interventional services. As a Radiology Partners-affiliated practice, Singleton Associates radiologists have access to advanced technology, artificial intelligence tools, quality programs, and clinical support resources that help deliver timely, high-quality care to patients throughout the state.

This agreement establishes a foundation for continued collaboration between Singleton Associates and BCBSTX and positions both organizations to advance high-quality healthcare delivery across Texas for years to come.

About Singleton Associates, P.A.

Singleton Associates got its start more than 65 years ago as the first radiology provider to offer 24/7 in-house services to hospitals to make sure patients received the radiological care they needed, when they needed it. Learn more at singletonassociates.radpartners.com.

About Radiology Partners

Radiology Partners, through its affiliated practices, is the leading technology-enabled radiology practice in the U.S., serving more than 3,400 hospitals and other healthcare facilities with high quality radiology, technology and artificial intelligence solutions. As a physician-led and physician-owned practice, our mission is to transform radiology by innovating across clinical value, technology, service and economics, while elevating the role of radiology and radiologists in healthcare. Using a proven healthcare services model, Radiology Partners provides consistent, high-quality care to patients, while delivering enhanced value to the hospitals, clinics, imaging centers and referring physicians we serve. Learn more at radpartners.com and connect with us on LinkedIn, X, Instagram and YouTube.

Rad to Rad Learning: Epidural Hematoma

The Radiology Partners (RP) Neuroradiology National Subspecialty Division (NSD) presents our newest Rad to Rad Learning case.

Peer Learning Opportunity

Rapid expansion is common reaching maximum size at 36 hours resulting in neurologic deficits and death in up to 5% due to herniations.

Hyperdense biconvex unilateral extra axial collection adjacent to a skull fracture in 75% of cases.

A grayscale scan of a human skull viewed from the front, showing the outline of the skull and cranial cavity with no visible internal detail or abnormalities—a valuable example for Rad to Rad Learning in radiographic interpretation.

Two CT brain scans: the left shows a front-facing (coronal) view, and the right shows a horizontal (axial) view, both revealing brain structures in grayscale with bone shown in white—an ideal example for Rad to Rad Learning.

Practical Insights

- Common “lucid interval” in up to 50% of cases.
- Typically associated with arterial laceration, but up to 10% are venous.
- Consider CTV if collection crosses suture.
- Bilateral EDH have up to 15-20% mortality rate.

Takeaway: Use bone window to look for fracture.

Shared to improve patient safety and healthcare delivery in the provision of radiology services. The circumstances and facts are changed, altered, or deidentified to preserve confidentiality. Privileges have not been waived.The Neuroradiology National Subspecialty Division (NSD) is part of RP’s Clinical Value Team, which works to elevate patient care and enhance value through innovation, collaboration and education. To advance this goal, our radiologists and advanced practice providers are committed to sharing peer learning as valuable reminders and insights about what we encounter in our day-to-day practice. Check back here and on X, LinkedIn and Instagram to see these common cases and our findings.